17-7-3　ⓔ文献

  1. Coiffier B, Lepage E, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large–B–cell lymphoma. N Engl J Med, 2002; 346: 235–242.

  2. Marcus R, Imrie K, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol, 2008; 26: 4579–4586.

  3. Marcus R, Davies A, et al: Obinutuzumab for the first–line treatment of follicular lymphoma. N Engl J Med, 2017; 377: 1331–1344.

  4. Wierda WG, Kipps TJ, et al: Ofatumumab as single–agent CD20 immunotherapy in fludarabine–refractory chronic lymphocytic leukemia. J Clin Oncol, 2010; 28: 1749–1755.

  5. Witzig TE, Gordon LI, et al: Randomized controlled trial of yttrium–90–labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low–grade, follicular, or transformed B–cell non–Hodgkin’s lymphoma. J Clin Oncol, 2002; 20: 2453–2463.

  6. Osterborg A, Foa R, et al: Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia, 2009; 23: 1980–1988.

  7. Younes A, Gopal AK, et al: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol, 2012; 30: 2183–2189.

  8. Ishida T, Joh T, et al: Defucosylated anti–CCR4 monoclonal antibody (KW-0761) for relapsed adult T–cell leukemia–lymphoma: a multicenter phase II study. J Clin Oncol, 2012; 30: 837–842.

  9. van Der Velden VH, te Marvelde JG, et al: Targeting of the CD33–calicheamicin immunoconjugate Mylotarg (CMA–676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood, 2001; 97: 3197–3204.

  10. Kantarjian HM, DeAngelo DJ, et al: Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med, 2016; 375: 740–753.

  11. Dimopoulos MA, Dytfeld D, et al: Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med, 2018; 379: 1811–1822.

  12. Dimopoulos MA, Oriol A, et al: Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med, 2016; 375: 1319–1331.

  13. Younes A, Santoro A, et al: Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem–cell transplantation and brentuximab vedotin: a multicentre, multicohort, single–arm phase 2 trial. Lancet Oncol, 2016; 17: 1283–1294.

  14. Chen R, Zinzani PL, et al: Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2–year follow–up of KEYNOTE–087. Blood, 2019; 134: 1144–1153.

  15. Kantarjian H, Stein A, et al: Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med, 2017; 376: 836–847.

  16. Druker BJ, Guilhot F, et al: Five-year follow–up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006; 355: 2408–2417.

  17. Saglio G, Kim DW, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med, 2010; 362: 2251–2259.

  18. Kantarjian H, Shah NP, et al: Dasatinib versus imatinib in newly diagnosed chronic–phase chronic myeloid leukemia. N Engl J Med, 2010; 362: 2260–2270.

  19. Cortes JE, Kim DW, et al: Bosutinib versus imatinib in newly diagnosed chronic–phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol, 2012; 30: 3486–3492.

  20. Cortes JE, Kantarjian H, et al: Ponatinib in refractory Philadelphia chromosome–positive leukemias. N Engl J Med, 2012; 367: 2075–2088.

  21. Verstovsek S, Mesa RA, et al: A double–blind, placebo–controlled trial of ruxolitinib for myelofibrosis. New Engl J Med, 2012; 366: 799–807.

  22. Byrd JC, Brown JR, et al: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med, 2014; 371: 213–223.

  23. Seymour JF, Kipps TJ, et al: Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med, 2018; 378: 1107–1120.

  24. Sanz MA, Fenaux P, et al: Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 2019; 133: 1630–1643.

  25. Takeshita A, Asou N, et al: Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG–APL204 study. Leukemia, 2019; 33: 358–370.

  26. Cortes JE, Khaled S, et al: Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3–ITD acute myeloid leukaemia (QuANTUM–R): a multicentre, randomised, controlled, open–label, phase 3 trial. Lancet Oncol, 2019; 20: 984–997.

  27. Perl AE, Martinelli G, et al: Gilteritinib or chemotherapy for relapsed or refractory FLT3–mutated AML. N Engl J Med, 2019; 381: 1728–1740.

  28. Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 2004; 5: 417–421.

  29. Fenaux P, Mufti GJ, et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher–risk myelodysplastic syndromes: a randomised, open–label, phase III study. Lancet Oncology, 2009; 10: 223–232.

  30. Olsen EA, Kim YH, et al: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T–cell lymphoma. J Clin Oncol, 2007; 25: 3109–3115.

  31. San–Miguel JF, Hungria VT, et al: Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double–blind phase 3 trial. Lancet Oncol, 2014; 15: 1195–1206.